Pathophysiology of neuropathic lysosomal storage disorders
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Although neurodegenerative diseases are most prevalent in the elderly, in rare cases, they can also affect children. Lysosomal storage diseases (LSDs) are a group of inherited metabolic neurodegenerative disorders due to deficiency of a specific protein integral to lysosomal function, such as enzymes or lysosomal components, or to errors in enzyme trafficking/targeting and defective function of nonenzymatic lysosomal proteins, all preventing the complete degradation and recycling of macromolecules. This primary metabolic event determines a cascade of secondary events, inducing LSD's pathology. The accumulation of intermediate degradation affects the function of lysosomes and other cellular organelles. Accumulation begins in infancy and progressively worsens, often affecting several organs, including the central nervous system (CNS). Affected neurons may die through apoptosis or necrosis, although neuronal loss usually does not occur before advanced stages of the disease. CNS pathology causes mental retardation, progressive neurodegeneration, and premature death. Many of these features are also found in adult neurodegenerative disorders, such as Alzheimer's, Parkinson's, and Huntington's diseases. However, the nature of the secondary events and their exact contribution to mental retardation and dementia remains largely unknown. Recently, lysosomal involvement in the pathogenesis of these disorders has been described. Improved knowledge of secondary events may have impact on diagnosis, staging, and follow‐up of affected children. Importantly, new insights may provide indications about possible disease reversal upon treatment. A discussion about the CNS pathophysiology involvement in LSDs is the aim of this review. The lysosomal involvement in adult neurodegenerative diseases will also be briefly described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 2×
“2008), mitochondrial dysfunction (Lin and Beal 2006), and altered calcium storage and endoplasmic reticulum (ER) functions (Mattson 2007).”
BackgroundSuppression of basal autophagy in neural cells causes neurodegenerative disease in mice
Hara, T., Nakamura, K., Matsui, M., Yamamoto, A., Nakahara, Y., Suzuki-Migishima, R., Yokoyama, M., Mishima, K., Saito, I., Okano, H., et al. (2006) · Nature · doi:10.1038/nature04724 · Cited by 3,882 · cited 2×
“In fact, inactivation of crucial autophagy genes in mice has been shown to lead to severe neurodegeneration and accumulation of undegraded polyubiquitinated proteins (Hara et al. 2006; Komatsu et al. 2006).”
BackgroundResultLoss of autophagy in the central nervous system causes neurodegeneration in mice
Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J.-I., Tanida, I., Ueno, T., Koike, M., Uchiyama, Y., Kominami, E., et al. (2006) · Nature · doi:10.1038/nature04723 · Cited by 3,500 · cited 2×
“In fact, inactivation of crucial autophagy genes in mice has been shown to lead to severe neurodegeneration and accumulation of undegraded polyubiquitinated proteins (Hara et al. 2006; Komatsu et al. 2006).”
BackgroundResultFadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166 · cited 2×
“disagreement with the normal response of macrophages in the clearance of apoptotic cells, which is anti-inflammatory in nature (Fadok et al. 1998).”
BackgroundResultA Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543 · cited 5×
“2004 b) or autophagy pathway play a very important role (Ravikumar et al. 2002; Rubinsztein et al. 2007; Sardiello et al. 2009; Zhang et al. 2009).”
BackgroundInfluentialPrevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 1×
“More results emphasize the concept that the lysosomal degradation pathway represents an alternative mechanism for the degradation of proteins, lipids, and damaged organelles and participates in α-synuclein clearance (Cuervo et al. 2004).”
BackgroundThe roles of intracellular protein-degradation pathways in neurodegeneration
Rubinsztein, D. C. (2006) · Nature · doi:10.1038/nature05291 · Cited by 1,625 · cited 2×
“…secondary changes in neurons, altered axonal transport (Coleman 2005), dysfunction of intracellular protein degradation and macroautophagy pathways (Rubinsztein 2006; Settembre et al. 2007; Settembre et al. 2008), mitochondrial dysfunction (Lin and Beal 2006), and altered calcium storage and…”
BackgroundPapanikolaou, G., & Pantopoulos, K. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.06.021 · Cited by 1,070 · cited 1×
“In particular, these proteins provide a state of cellular equilibrium whereby iron is readily available for all metabolic functions but sheltered from taking part in cytotoxic ROS-generating reactions (Papanikolaou and Pantopoulos 2005; Lee et al. 2006; Nadadur et al. 2008).”
BackgroundAxon degeneration mechanisms: Commonality amid diversity
Coleman, M. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1788 · Cited by 819 · cited 2×
“…is not just a simple and isolated phenomenon; more events associate with it as secondary changes in neurons, altered axonal transport (Coleman 2005), dysfunction of intracellular protein degradation and macroautophagy pathways (Rubinsztein 2006; Settembre et al. 2007; Settembre et…”
Background
Cited by
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Blood–brain barrier structure and function and the challenges for CNS drug delivery
Abbott, N. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9608-0 · Cited by 909
Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity
Stern, S. T., Adiseshaiah, P. P., & Crist, R. M. (2012) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-9-20 · Cited by 836
The lysosome: from waste bag to potential therapeutic target
Appelqvist, H., Wäster, P., Kågedal, K., & Öllinger, K. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt022 · Cited by 772
Lysosomal storage disorders: The cellular impact of lysosomal dysfunction
Platt, F. M., Boland, B., & van der Spoel, A. C. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201208152 · Cited by 689
The Lysosome as a Regulatory Hub
Perera, R. M., & Zoncu, R. (2016) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-111315-125125 · Cited by 660
Necrotic, apoptotic and autophagic cell fates triggered by nanoparticles
Mohammadinejad, R., Moosavi, M. A., Tavakol, S., Vardar, D. Ö., Hosseini, A., Rahmati, M., Dini, L., Hussain, S., Mandegary, A., & Klionsky, D. J. (2019) · Autophagy · doi:10.1080/15548627.2018.1509171 · Cited by 453
Nixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
Muldoon, L. L., Alvarez, J. I., Begley, D. J., Boado, R. J., del Zoppo, G. J., Doolittle, N. D., Engelhardt, B., Hallenbeck, J. M., Lonser, R. R., Ohlfest, J. R., et al. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.153 · Cited by 321
Self-citationAdeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
“Although individually rare, they have a collective incidence of approximately 1 per 7000 live births,(26) and at least 70% of all LSDs have a significant CNS component that is typically characterized by neuroinflammation and neurodegeneration in multiple brain regions.(27) Several features of LSDs make them ideal cand…”
BackgroundAmyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis
Pimplikar, S. W., Nixon, R. A., Robakis, N. K., Shen, J., & Tsai, L.-H. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4305-10.2010 · Cited by 281
Ullman, J. C., Arguello, A., Getz, J. A., Bhalla, A., Mahon, C. S., Wang, J., Giese, T., Bedard, C., Kim, D. J., Blumenfeld, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1163 · Cited by 205
“We also demonstrate that enhanced brain exposure of IDS translates to effective reduction of accumulated substrates and correction of downstream pathology in the CNS in a mouse model of MPS II disease, highlighting the therapeutic potential of the ETV approach for MPS II and potentially other neuronopathic LSDs. RESUL…”
BackgroundInfluentialThe Ubiquitin-Proteasome System and the Autophagic-Lysosomal System in Alzheimer Disease
Ihara, Y., Morishima-Kawashima, M., & Nixon, R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006361 · Cited by 190
Sensitivity to Lysosome-Dependent Cell Death Is Directly Regulated by Lysosomal Cholesterol Content
Appelqvist, H., Sandin, L., Björnström, K., Saftig, P., Garner, B., Öllinger, K., & Kågedal, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050262 · Cited by 108
“The reason for the neuronal vulnerability has not been elucidated, but neurons seem to be particularly susceptible to disturbances of lysosomal function [35,36], and cholesterol storage in lysosomes induces additional changes in the lysosomal system.”
BackgroundPathogenesis, emerging therapeutic targets and treatment in sialidosis
D’Azzo, A., Machado, E., & Annunziata, I. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1025746 · Cited by 76
Trends in glycolipid biomarker discovery in neurodegenerative disorders by mass spectrometry
Dehelean, L., Sarbu, M., Petrut, A., & Zamfir, A. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_42 · Cited by 16
Metadata
- Authors
- Bellettato, C. M., & Scarpa, M.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2010-04-29
- Volume
- 33
- Issue
- 4
- Pages
- 347-362
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2011501261
- Cited by
- 141
- References
- 20
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.